Vitrolife AB · OMXSTO:VITR

Vitrolife AB — Q3 2020 Earnings Presentation

9 slides from Vitrolife AB's earnings presentation, Nov 6, 2020

  1. Slide 1: Vitrolife AB (publ) Interim report January - September 2020

    VITROLIFE AB (PUBL) Interim report January - September 2020 2020-11-06 Thomas Axelsson, CEO Mikael Engblom, CFO 1

  2. Slide 2: Good profitability and continued recovery

    GOOD PROFITABILITY AND CONTINUED RECOVERY Q3:  Sales of 320 MSEK (378) equals -15% in SEK.  Sales decreased by 11% in local currency.  EBITDA of 134 MSEK (155) corresponding to a margin of 42% (41). January - September:  Sales of 863 MSEK (1 071) equals -19% in SEK.  Sales decreased by 19% in l

  3. Slide 3: Sales and growth per market region

    SALES AND GROWTH PER MARKET REGION SHARE OF VITROLIFE’S SALES 19% 42% 22% 17% ROLLING 12-MONTHS Q3 GROWTH RATE COMPARED TO LAST YEAR IN LOCAL CURRENCIES -6% -4% -14% -27% Total -11%* 3 * Whereof organic growth -11 percent

  4. Slide 4: Current situation and short-term outlook

    CURRENT SITUATION AND SHORT-TERM OUTLOOK  The company estimates that the number of treatments globally during the third quarter amounted to approximately 90% of the same period last year.  Large regional differences in recovery.  Recovery is driven by easing of restrictions in many countries and

  5. Slide 5: Sales and growth per division

    SALES AND GROWTH PER DIVISION SEK millions, rolling 12m 1600 1400 125 136 91 1200 20 54 116 109 GENOMICS -13% 442 488 506 1000 398 342 355 352 446 391 TECHNOLOGY -41% 800 600 400 737 772 802 820 834 842 835 746 750 CONSUMABLES +7% 200 0 Quarterly growth, Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 local currency 201

  6. Slide 6: Key financials Group Q3

    KEY FINANCIALS GROUP Q3 • Fluctuations in exchange rates negatively impacted EBITDA by 9 MSEK. • Gross margin impacted by negative economies of scale. • EBITDA positively impacted by reduced bad debt provision (5 MSEK) and reduced activity costs (travel, exhibitions etc). • Cash and cash equivalents

  7. Slide 7: Long-term outlook

    LONG-TERM OUTLOOK  Long-term market growth 5-10% in monetary terms  Expansion of sales  Broadening the product offering 7

  8. Slide 8: Contact

    Contact: Thomas Axelsson, CEO, taxelsson@vitrolife.com, +46 31 721 80 01 Mikael Engblom, CFO, mengblom@vitrolife.com, +46 31 721 80 14

  9. Slide 9: Disclaimer

    DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i

Vitrolife — Q3 2020 Earnings Presentation on 6ix